[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fVqCfPdkvT1_sBizUTPnRLaJlFpTHcBOSMVws1rmv5tQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"University of New Mexico",[4],310,false,36,8,1108901,7,219,[14,17,20,22,24,26,29,32],{"name":15,"count":16},"Cancer",14,{"name":18,"count":19},"Obesity",10,{"name":21,"count":9},"Lung Diseases",{"name":23,"count":11},"Chronic Pain",{"name":25,"count":11},"Contraception",{"name":27,"count":28},"Depression",6,{"name":30,"count":31},"Traumatic Brain Injury",5,{"name":33,"count":31},"Diabetes Mellitus",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06934642","Effect of Tirzepatide on Markers of MASLD in Patients With Obesity","2026-08","Tirzepatide",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06268704","Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection","2027-01-01","Dexamethasone",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05219175","MDMA for Co-occurring PTSD and OUD After Childbirth","2027-04","MDMA Assisted Therapy",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07506395","Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","2027-05-01","Psilocybin",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03908736","Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation","2027-07","Zinc Picolinate 15 Mg",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,108,138,156,179,210,230,253,288,323,345,363,388,413,436,454,472,499,517,544,562,587,615,633,659,677,704,722,747,773,791,815,833,865,891,909,934,975,1013,1047,1072,1090,1114,1141,1159,1177,1195,1217,1242,1269,1287,1305,1330,1348,1371,1397,1415,1433,1451,1474,1497,1523,1541,1566,1584,1602,1620,1643,1677,1701,1725,1743,1761,1779,1803,1829,1852,1876,1904,1922,1946,1970,1996,2021,2045,2071,2094,2118,2168,2207,2263,2296,2318,2343,2361,2383,2401,2426,2444,2469,2491,2517,2535,2553,2571,2589,2607,2625,2643,2661,2679,2697,2715,2733,2751,2769,2787,2805,2823,2841,2859,2877,2895,2913,2931,2949,2967,2985,3003,3021,3039,3063,3089,3112,3130,3156,3174,3201,3226,3244,3267,3292,3310,3334,3356,3380],{"intervention":69,"totalTrials":70,"cells":71},"Methylprednisolone",2,{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":77,"PHASE3":91,"PHASE4":93,"NA":106},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[],{"trials":78,"activeCount":74},[79],{"nctId":80,"briefTitle":81,"status":82,"phases":83,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":90},"NCT00128180","Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome","COMPLETED",[63],"2010-12","2011-10","2003-01",66,[89],"Hantavirus Infections",[69],{"trials":92,"activeCount":74},[],{"trials":94,"activeCount":105,"soonestReadout":43},[95],{"nctId":41,"briefTitle":42,"status":96,"phases":97,"primaryCompletion":43,"completion":53,"start":98,"enrollment":99,"conditions":100,"interventions":103},"RECRUITING",[65],"2024-03-27",230,[101,102],"Sacroiliac Joint Dysfunction","Sacro-Iliac Spondylosis",[44,69,104],"2% Lidocaine HCl",1,{"trials":107,"activeCount":74},[],{"intervention":44,"totalTrials":70,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":136},{"trials":111,"activeCount":74},[],{"trials":113,"activeCount":74},[],{"trials":115,"activeCount":74},[],{"trials":117,"activeCount":74},[],{"trials":119,"activeCount":105,"soonestReadout":43},[120,132],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":74,"conditions":127,"interventions":130},"NCT01511211","Duration of Leg Nerve Blocks With Dexamethasone Added to Local Anesthetic","WITHDRAWN",[65],"2013-08","2012-09",[128,129],"Pain","Total Knee Arthroplasty",[44,131],"Ropivacaine",{"nctId":41,"briefTitle":42,"status":96,"phases":133,"primaryCompletion":43,"completion":53,"start":98,"enrollment":99,"conditions":134,"interventions":135},[65],[101,102],[44,69,104],{"trials":137,"activeCount":74},[],{"intervention":104,"totalTrials":105,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":154},{"trials":141,"activeCount":74},[],{"trials":143,"activeCount":74},[],{"trials":145,"activeCount":74},[],{"trials":147,"activeCount":74},[],{"trials":149,"activeCount":105,"soonestReadout":43},[150],{"nctId":41,"briefTitle":42,"status":96,"phases":151,"primaryCompletion":43,"completion":53,"start":98,"enrollment":99,"conditions":152,"interventions":153},[65],[101,102],[44,69,104],{"trials":155,"activeCount":74},[],{"intervention":49,"totalTrials":105,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":159,"activeCount":74},[],{"trials":161,"activeCount":74},[],{"trials":163,"activeCount":105,"soonestReadout":48},[164],{"nctId":46,"briefTitle":47,"status":96,"phases":165,"primaryCompletion":48,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":172},[63],"2027-11","2024-04-16",15,[170,171],"Stress Disorders, Post-Traumatic","Opioid Use Disorder",[49],{"trials":174,"activeCount":74},[],{"trials":176,"activeCount":74},[],{"trials":178,"activeCount":74},[],{"intervention":54,"totalTrials":70,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":192,"PHASE3":204,"PHASE4":206,"NA":208},{"trials":182,"activeCount":74},[],{"trials":184,"activeCount":105,"soonestReadout":53},[185],{"nctId":51,"briefTitle":52,"status":96,"phases":186,"primaryCompletion":53,"completion":187,"start":188,"enrollment":8,"conditions":189,"interventions":191},[62],"2028-05-01","2026-05-01",[190],"PTSD",[54],{"trials":193,"activeCount":74},[194],{"nctId":195,"briefTitle":196,"status":82,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":19,"conditions":201,"interventions":203},"NCT01534494","Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence",[63],"2013-09","2014-03","2012-01",[202],"Alcohol Dependence",[54],{"trials":205,"activeCount":74},[],{"trials":207,"activeCount":74},[],{"trials":209,"activeCount":74},[],{"intervention":39,"totalTrials":105,"cells":211},{"EARLY_PHASE1":212,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":213,"activeCount":105,"soonestReadout":38},[214],{"nctId":36,"briefTitle":37,"status":96,"phases":215,"primaryCompletion":38,"completion":38,"start":216,"enrollment":9,"conditions":217,"interventions":219},[61],"2025-06-30",[218,18],"MASLD",[39],{"trials":221,"activeCount":74},[],{"trials":223,"activeCount":74},[],{"trials":225,"activeCount":74},[],{"trials":227,"activeCount":74},[],{"trials":229,"activeCount":74},[],{"intervention":59,"totalTrials":105,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":242},{"trials":233,"activeCount":74},[],{"trials":235,"activeCount":74},[],{"trials":237,"activeCount":74},[],{"trials":239,"activeCount":74},[],{"trials":241,"activeCount":74},[],{"trials":243,"activeCount":105,"soonestReadout":58},[244],{"nctId":56,"briefTitle":57,"status":96,"phases":245,"primaryCompletion":58,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":252},[66],"2027-12","2019-05-19",100,[250,251],"DNA Damage","Immune System Disorder",[59],{"intervention":254,"totalTrials":70,"cells":255},"Angiotensin II",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":286},{"trials":257,"activeCount":74},[],{"trials":259,"activeCount":74},[],{"trials":261,"activeCount":74},[],{"trials":263,"activeCount":74},[],{"trials":265,"activeCount":74},[266,276],{"nctId":267,"briefTitle":268,"status":123,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":74,"conditions":272,"interventions":274},"NCT05193370","Angiotensin II vs. Vasopressin in Septic Shock",[65],"2022-11-30","2022-01-03",[273],"Septic Shock",[254,275],"Vasopressin",{"nctId":277,"briefTitle":278,"status":82,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT05824767","Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock",[65],"2025-03-12","2023-04-17",40,[273,284],"Vasodilatory Shock",[254],{"trials":287,"activeCount":74},[],{"intervention":289,"totalTrials":70,"cells":290},"sildenafil",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":321},{"trials":292,"activeCount":74},[],{"trials":294,"activeCount":74},[],{"trials":296,"activeCount":74},[],{"trials":298,"activeCount":74},[],{"trials":300,"activeCount":74},[301,310],{"nctId":302,"briefTitle":303,"status":82,"phases":304,"completion":305,"start":306,"enrollment":248,"conditions":307,"interventions":309},"NCT00375297","Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women",[65],"2005-06","2001-01",[308,27],"Sexual Dysfunction",[289],{"nctId":311,"briefTitle":312,"status":123,"phases":313,"primaryCompletion":314,"completion":315,"start":316,"enrollment":74,"conditions":317,"interventions":319},"NCT00793338","Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure",[65],"2010-11","2011-02","2008-11",[318],"Heart Failure",[320],"Sildenafil",{"trials":322,"activeCount":74},[],{"intervention":324,"totalTrials":105,"cells":325},"Acamprosate",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":343},{"trials":327,"activeCount":74},[],{"trials":329,"activeCount":74},[],{"trials":331,"activeCount":74},[],{"trials":333,"activeCount":74},[],{"trials":335,"activeCount":74},[336],{"nctId":337,"briefTitle":338,"status":123,"phases":339,"primaryCompletion":340,"completion":340,"start":340,"enrollment":74,"conditions":341,"interventions":342},"NCT00655967","Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)",[65],"2006-12",[202],[324,324],{"trials":344,"activeCount":74},[],{"intervention":131,"totalTrials":105,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":361},{"trials":348,"activeCount":74},[],{"trials":350,"activeCount":74},[],{"trials":352,"activeCount":74},[],{"trials":354,"activeCount":74},[],{"trials":356,"activeCount":74},[357],{"nctId":121,"briefTitle":122,"status":123,"phases":358,"primaryCompletion":125,"completion":125,"start":126,"enrollment":74,"conditions":359,"interventions":360},[65],[128,129],[44,131],{"trials":362,"activeCount":74},[],{"intervention":364,"totalTrials":105,"cells":365},"disulfiram plus lorazepam",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":386},{"trials":367,"activeCount":74},[],{"trials":369,"activeCount":74},[],{"trials":371,"activeCount":74},[],{"trials":373,"activeCount":74},[],{"trials":375,"activeCount":74},[376],{"nctId":377,"briefTitle":378,"status":82,"phases":379,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT00721526","Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder",[65],"2012-08","2009-08",41,[202,384],"Anxiety Disorder",[364],{"trials":387,"activeCount":74},[],{"intervention":389,"totalTrials":105,"cells":390},"Lumateperone",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":411},{"trials":392,"activeCount":74},[],{"trials":394,"activeCount":74},[],{"trials":396,"activeCount":74},[],{"trials":398,"activeCount":74},[],{"trials":400,"activeCount":74},[401],{"nctId":402,"briefTitle":403,"status":123,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":74,"conditions":407,"interventions":409},"NCT05890768","Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine",[65],"2024-02-28","2023-05-11",[408],"Psychosis",[389,410],"Risperidone",{"trials":412,"activeCount":74},[],{"intervention":414,"totalTrials":105,"cells":415},"Ropivacine and Chloroprocaine mixture",{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":422,"PHASE4":424,"NA":434},{"trials":417,"activeCount":74},[],{"trials":419,"activeCount":74},[],{"trials":421,"activeCount":74},[],{"trials":423,"activeCount":74},[],{"trials":425,"activeCount":74},[426],{"nctId":427,"briefTitle":428,"status":82,"phases":429,"primaryCompletion":314,"completion":314,"start":381,"enrollment":430,"conditions":431,"interventions":432},"NCT01719237","Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture",[65],60,[128],[414,433],"Ropivacaine only",{"trials":435,"activeCount":74},[],{"intervention":433,"totalTrials":105,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":452},{"trials":439,"activeCount":74},[],{"trials":441,"activeCount":74},[],{"trials":443,"activeCount":74},[],{"trials":445,"activeCount":74},[],{"trials":447,"activeCount":74},[448],{"nctId":427,"briefTitle":428,"status":82,"phases":449,"primaryCompletion":314,"completion":314,"start":381,"enrollment":430,"conditions":450,"interventions":451},[65],[128],[414,433],{"trials":453,"activeCount":74},[],{"intervention":275,"totalTrials":105,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":470},{"trials":457,"activeCount":74},[],{"trials":459,"activeCount":74},[],{"trials":461,"activeCount":74},[],{"trials":463,"activeCount":74},[],{"trials":465,"activeCount":74},[466],{"nctId":267,"briefTitle":268,"status":123,"phases":467,"primaryCompletion":270,"completion":270,"start":271,"enrollment":74,"conditions":468,"interventions":469},[65],[273],[254,275],{"trials":471,"activeCount":74},[],{"intervention":473,"totalTrials":105,"cells":474},"carvedilol",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":497},{"trials":476,"activeCount":74},[],{"trials":478,"activeCount":74},[],{"trials":480,"activeCount":74},[],{"trials":482,"activeCount":74},[],{"trials":484,"activeCount":74},[485],{"nctId":486,"briefTitle":487,"status":82,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":495},"NCT00642434","Comparison of Blood Pressure Medications on Metabolism",[65],"2008-06","2008-07","2004-01",22,[494],"Diabetes",[473,496],"metoprolol",{"trials":498,"activeCount":74},[],{"intervention":496,"totalTrials":105,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":515},{"trials":502,"activeCount":74},[],{"trials":504,"activeCount":74},[],{"trials":506,"activeCount":74},[],{"trials":508,"activeCount":74},[],{"trials":510,"activeCount":74},[511],{"nctId":486,"briefTitle":487,"status":82,"phases":512,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":513,"interventions":514},[65],[494],[473,496],{"trials":516,"activeCount":74},[],{"intervention":518,"totalTrials":105,"cells":519},"Ondansetron",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":542},{"trials":521,"activeCount":74},[],{"trials":523,"activeCount":74},[],{"trials":525,"activeCount":74},[],{"trials":527,"activeCount":74},[],{"trials":529,"activeCount":74},[530],{"nctId":531,"briefTitle":532,"status":82,"phases":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":540},"NCT00429832","A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department",[65],"2005-11","2003-10",120,[538,539],"Nausea","Vomiting",[518,541],"promethazine",{"trials":543,"activeCount":74},[],{"intervention":541,"totalTrials":105,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":560},{"trials":547,"activeCount":74},[],{"trials":549,"activeCount":74},[],{"trials":551,"activeCount":74},[],{"trials":553,"activeCount":74},[],{"trials":555,"activeCount":74},[556],{"nctId":531,"briefTitle":532,"status":82,"phases":557,"completion":534,"start":535,"enrollment":536,"conditions":558,"interventions":559},[65],[538,539],[518,541],{"trials":561,"activeCount":74},[],{"intervention":563,"totalTrials":105,"cells":564},"Etonogestrel",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":573,"NA":585},{"trials":566,"activeCount":74},[],{"trials":568,"activeCount":74},[],{"trials":570,"activeCount":74},[],{"trials":572,"activeCount":74},[],{"trials":574,"activeCount":74},[575],{"nctId":576,"briefTitle":577,"status":82,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT03978598","Breastfeeding Etonogestrel Implant Study",[65],"2024-06-04","2024-09-19","2019-06-03",150,[25],[563],{"trials":586,"activeCount":74},[],{"intervention":588,"totalTrials":105,"cells":589},"Acetaminophen",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":613},{"trials":591,"activeCount":74},[],{"trials":593,"activeCount":74},[],{"trials":595,"activeCount":74},[],{"trials":597,"activeCount":74},[],{"trials":599,"activeCount":74},[600],{"nctId":601,"briefTitle":602,"status":82,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":248,"conditions":607,"interventions":611},"NCT02911701","Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features",[65],"2017-11-07","2018-01-10","2016-09",[608,609,610],"Pre-Eclampsia","HELLP Syndrome","Eclampsia",[588,612],"Ibuprofen",{"trials":614,"activeCount":74},[],{"intervention":612,"totalTrials":105,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":631},{"trials":618,"activeCount":74},[],{"trials":620,"activeCount":74},[],{"trials":622,"activeCount":74},[],{"trials":624,"activeCount":74},[],{"trials":626,"activeCount":74},[627],{"nctId":601,"briefTitle":602,"status":82,"phases":628,"primaryCompletion":604,"completion":605,"start":606,"enrollment":248,"conditions":629,"interventions":630},[65],[608,609,610],[588,612],{"trials":632,"activeCount":74},[],{"intervention":634,"totalTrials":105,"cells":635},"montelukast vs pretreatment with albuterol",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":657},{"trials":637,"activeCount":74},[],{"trials":639,"activeCount":74},[],{"trials":641,"activeCount":74},[],{"trials":643,"activeCount":74},[],{"trials":645,"activeCount":74},[646],{"nctId":647,"briefTitle":648,"status":82,"phases":649,"primaryCompletion":650,"completion":650,"start":651,"enrollment":652,"conditions":653,"interventions":655},"NCT00273689","Exercise Induced Bronchospasm in Children",[65],"2007-09","2005-12",13,[654],"Exercise Induced Bronchospasm",[634,656],"montelukast",{"trials":658,"activeCount":74},[],{"intervention":656,"totalTrials":105,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":675},{"trials":662,"activeCount":74},[],{"trials":664,"activeCount":74},[],{"trials":666,"activeCount":74},[],{"trials":668,"activeCount":74},[],{"trials":670,"activeCount":74},[671],{"nctId":647,"briefTitle":648,"status":82,"phases":672,"primaryCompletion":650,"completion":650,"start":651,"enrollment":652,"conditions":673,"interventions":674},[65],[654],[634,656],{"trials":676,"activeCount":74},[],{"intervention":678,"totalTrials":105,"cells":679},"Morphine",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":702},{"trials":681,"activeCount":74},[],{"trials":683,"activeCount":74},[],{"trials":685,"activeCount":74},[],{"trials":687,"activeCount":74},[],{"trials":689,"activeCount":74},[690],{"nctId":691,"briefTitle":692,"status":82,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT02851303","Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome",[65],"2018-06","2018-09-30","2016-10",61,[699],"Neonatal Abstinence Syndrome",[678,701],"Methadone",{"trials":703,"activeCount":74},[],{"intervention":701,"totalTrials":105,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":720},{"trials":707,"activeCount":74},[],{"trials":709,"activeCount":74},[],{"trials":711,"activeCount":74},[],{"trials":713,"activeCount":74},[],{"trials":715,"activeCount":74},[716],{"nctId":691,"briefTitle":692,"status":82,"phases":717,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":718,"interventions":719},[65],[699],[678,701],{"trials":721,"activeCount":74},[],{"intervention":723,"totalTrials":105,"cells":724},"Probiotic dietary supplement",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":743,"NA":745},{"trials":726,"activeCount":74},[],{"trials":728,"activeCount":74},[],{"trials":730,"activeCount":74},[],{"trials":732,"activeCount":74},[733],{"nctId":734,"briefTitle":735,"status":82,"phases":736,"primaryCompletion":737,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":742},"NCT04721912","Group B Streptococcus Response After Probiotic Exposure",[64],"2023-08-31","2020-12-24",68,[741],"Group B Strep Infection",[723],{"trials":744,"activeCount":74},[],{"trials":746,"activeCount":74},[],{"intervention":748,"totalTrials":105,"cells":749},"Nalmefene",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":769,"NA":771},{"trials":751,"activeCount":74},[],{"trials":753,"activeCount":74},[],{"trials":755,"activeCount":74},[],{"trials":757,"activeCount":74},[758],{"nctId":759,"briefTitle":760,"status":123,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":74,"conditions":764,"interventions":767},"NCT06408714","Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose",[64],"2024-12-09","2024-08-26",[765,766],"Opioid Overdose","Opiate Overdose",[748,768],"Naloxone",{"trials":770,"activeCount":74},[],{"trials":772,"activeCount":74},[],{"intervention":768,"totalTrials":105,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":787,"NA":789},{"trials":776,"activeCount":74},[],{"trials":778,"activeCount":74},[],{"trials":780,"activeCount":74},[],{"trials":782,"activeCount":74},[783],{"nctId":759,"briefTitle":760,"status":123,"phases":784,"primaryCompletion":762,"completion":762,"start":763,"enrollment":74,"conditions":785,"interventions":786},[64],[765,766],[748,768],{"trials":788,"activeCount":74},[],{"trials":790,"activeCount":74},[],{"intervention":792,"totalTrials":105,"cells":793},"Prednisone, Vinblastin, 6-mercaptopuroine",{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":811,"NA":813},{"trials":795,"activeCount":74},[],{"trials":797,"activeCount":74},[],{"trials":799,"activeCount":74},[],{"trials":801,"activeCount":74},[802],{"nctId":803,"briefTitle":804,"status":123,"phases":805,"primaryCompletion":806,"completion":806,"start":806,"enrollment":74,"conditions":807,"interventions":809},"NCT00488605","H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis",[64],"2023-08-01",[808],"Leukemia",[792,810],"Leucovorin, Methotrexate, Vinblastine, Prednisone",{"trials":812,"activeCount":74},[],{"trials":814,"activeCount":74},[],{"intervention":810,"totalTrials":105,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":829,"NA":831},{"trials":818,"activeCount":74},[],{"trials":820,"activeCount":74},[],{"trials":822,"activeCount":74},[],{"trials":824,"activeCount":74},[825],{"nctId":803,"briefTitle":804,"status":123,"phases":826,"primaryCompletion":806,"completion":806,"start":806,"enrollment":74,"conditions":827,"interventions":828},[64],[808],[792,810],{"trials":830,"activeCount":74},[],{"trials":832,"activeCount":74},[],{"intervention":834,"totalTrials":105,"cells":835},"Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":861,"NA":863},{"trials":837,"activeCount":74},[],{"trials":839,"activeCount":74},[],{"trials":841,"activeCount":74},[],{"trials":843,"activeCount":74},[844],{"nctId":845,"briefTitle":846,"status":82,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":860},"NCT04048356","Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures",[64],"2021-02-28","2021-03-14","2019-07-15",137,[853,854,855,856,857,858,859],"Pelvic Organ Prolapse","Urinary Incontinence","Pelvic Floor Disorders","Gynecologic Disease","Post-Op Infection","Surgical Site Infection","Urinary Tract Infections",[834],{"trials":862,"activeCount":74},[],{"trials":864,"activeCount":74},[],{"intervention":866,"totalTrials":105,"cells":867},"arformoterol",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":887,"NA":889},{"trials":869,"activeCount":74},[],{"trials":871,"activeCount":74},[],{"trials":873,"activeCount":74},[],{"trials":875,"activeCount":74},[876],{"nctId":877,"briefTitle":878,"status":123,"phases":879,"primaryCompletion":880,"completion":881,"start":882,"enrollment":74,"conditions":883,"interventions":885},"NCT00662779","Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)",[64],"2009-03","2009-07","2008-04",[884],"Exercise-induced Bronchospasm",[866,886],"formoterol",{"trials":888,"activeCount":74},[],{"trials":890,"activeCount":74},[],{"intervention":886,"totalTrials":105,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":905,"NA":907},{"trials":894,"activeCount":74},[],{"trials":896,"activeCount":74},[],{"trials":898,"activeCount":74},[],{"trials":900,"activeCount":74},[901],{"nctId":877,"briefTitle":878,"status":123,"phases":902,"primaryCompletion":880,"completion":881,"start":882,"enrollment":74,"conditions":903,"interventions":904},[64],[884],[866,886],{"trials":906,"activeCount":74},[],{"trials":908,"activeCount":74},[],{"intervention":910,"totalTrials":105,"cells":911},"Trimo-San gel",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":930,"NA":932},{"trials":913,"activeCount":74},[],{"trials":915,"activeCount":74},[],{"trials":917,"activeCount":74},[],{"trials":919,"activeCount":74},[920],{"nctId":921,"briefTitle":922,"status":82,"phases":923,"primaryCompletion":924,"completion":924,"start":925,"enrollment":926,"conditions":927,"interventions":929},"NCT01471457","Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis",[63,64],"2014-09","2009-09",184,[928],"Bacterial Vaginosis",[910],{"trials":931,"activeCount":74},[],{"trials":933,"activeCount":74},[],{"intervention":935,"totalTrials":70,"cells":936},"Darbepoetin Alfa",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":938,"activeCount":74},[],{"trials":940,"activeCount":74},[],{"trials":942,"activeCount":74},[943,956],{"nctId":944,"briefTitle":945,"status":82,"phases":946,"primaryCompletion":947,"completion":948,"start":949,"enrollment":950,"conditions":951,"interventions":953},"NCT00334737","Darbepoetin Administration to Preterm Infants",[63],"2013-12","2014-06","2006-06",102,[952],"Infant, Newborn",[935,954,955],"erythropoietin alfa","sham",{"nctId":957,"briefTitle":958,"status":82,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":967},"NCT03071861","Mild Encephalopathy in the Newborn Treated With Darbepoetin",[63],"2019-12-01","2022-09-01","2017-12-01",28,[965,966],"Neonatal Encephalopathy","Hypoxic-Ischemic Encephalopathy Mild",[935,968],"Normal Saline",{"trials":970,"activeCount":74},[],{"trials":972,"activeCount":74},[],{"trials":974,"activeCount":74},[],{"intervention":976,"totalTrials":70,"cells":977},"estramustine phosphate sodium",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":993,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":979,"activeCount":74},[],{"trials":981,"activeCount":74},[982],{"nctId":983,"briefTitle":984,"status":82,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":991},"NCT00002721","Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer",[62],"2013-06","1995-03",18,[990],"Prostate Cancer",[992,976],"doxorubicin hydrochloride",{"trials":994,"activeCount":74},[995],{"nctId":996,"briefTitle":997,"status":82,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},"NCT00003584","Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and\u002For Metastatic Kidney Cancer",[63],"2000-12","1998-07",35,[1003],"Kidney Cancer",[976,1005,1006],"prednisone","vinorelbine tartrate",{"trials":1008,"activeCount":74},[],{"trials":1010,"activeCount":74},[],{"trials":1012,"activeCount":74},[],{"intervention":1014,"totalTrials":70,"cells":1015},"Hydroxychloroquine",{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1017,"activeCount":74},[],{"trials":1019,"activeCount":74},[],{"trials":1021,"activeCount":74},[1022,1032],{"nctId":1023,"briefTitle":1024,"status":1025,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":105,"conditions":1029,"interventions":1031},"NCT04435808","Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19","TERMINATED",[62,63],"2020-07-15","2020-04-14",[1030],"COVID-19",[1014],{"nctId":1033,"briefTitle":1034,"status":1025,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":963,"conditions":1038,"interventions":1039},"NCT04458948","Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients",[63],"2020-08-28","2020-03-24",[1030],[1014,1040],"Azithromycin",{"trials":1042,"activeCount":74},[],{"trials":1044,"activeCount":74},[],{"trials":1046,"activeCount":74},[],{"intervention":1048,"totalTrials":105,"cells":1049},"Isoxsuprine Hydrochloride",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1051,"activeCount":74},[],{"trials":1053,"activeCount":74},[],{"trials":1055,"activeCount":74},[1056],{"nctId":1057,"briefTitle":1058,"status":82,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":70,"conditions":1062,"interventions":1064},"NCT03752307","Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses",[62,63],"2023-07-06","2019-02-15",[1063],"Multiple Sclerosis",[1048,1065],"Corticosteroid",{"trials":1067,"activeCount":74},[],{"trials":1069,"activeCount":74},[],{"trials":1071,"activeCount":74},[],{"intervention":1065,"totalTrials":105,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1075,"activeCount":74},[],{"trials":1077,"activeCount":74},[],{"trials":1079,"activeCount":74},[1080],{"nctId":1057,"briefTitle":1058,"status":82,"phases":1081,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":70,"conditions":1082,"interventions":1083},[62,63],[1063],[1048,1065],{"trials":1085,"activeCount":74},[],{"trials":1087,"activeCount":74},[],{"trials":1089,"activeCount":74},[],{"intervention":1091,"totalTrials":105,"cells":1092},"Gemcitabine, Irinotecan, Allopurinol.",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1094,"activeCount":74},[],{"trials":1096,"activeCount":74},[],{"trials":1098,"activeCount":74},[1099],{"nctId":1100,"briefTitle":1101,"status":82,"phases":1102,"primaryCompletion":305,"completion":1103,"start":1104,"enrollment":492,"conditions":1105,"interventions":1107},"NCT00276003","INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.",[63],"2005-08","2002-08",[1106,15],"Non-Hodgkin's Lymphoma",[1091],{"trials":1109,"activeCount":74},[],{"trials":1111,"activeCount":74},[],{"trials":1113,"activeCount":74},[],{"intervention":1115,"totalTrials":105,"cells":1116},"0.9% Normal Saline (0.9% Sodium Chloride)",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1118,"activeCount":74},[],{"trials":1120,"activeCount":74},[],{"trials":1122,"activeCount":74},[1123],{"nctId":1124,"briefTitle":1125,"status":82,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1133},"NCT02668952","Fluid Chloride and AKI in Cardiopulmonary Bypass",[63],"2017-02-04","2018-02","2016-01",30,[1132],"Acute Kidney Injury",[1115,1134],"Isolyte S",{"trials":1136,"activeCount":74},[],{"trials":1138,"activeCount":74},[],{"trials":1140,"activeCount":74},[],{"intervention":1134,"totalTrials":105,"cells":1142},{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1144,"activeCount":74},[],{"trials":1146,"activeCount":74},[],{"trials":1148,"activeCount":74},[1149],{"nctId":1124,"briefTitle":1125,"status":82,"phases":1150,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1151,"interventions":1152},[63],[1132],[1115,1134],{"trials":1154,"activeCount":74},[],{"trials":1156,"activeCount":74},[],{"trials":1158,"activeCount":74},[],{"intervention":954,"totalTrials":105,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1171,"PHASE4":1173,"NA":1175},{"trials":1162,"activeCount":74},[],{"trials":1164,"activeCount":74},[],{"trials":1166,"activeCount":74},[1167],{"nctId":944,"briefTitle":945,"status":82,"phases":1168,"primaryCompletion":947,"completion":948,"start":949,"enrollment":950,"conditions":1169,"interventions":1170},[63],[952],[935,954,955],{"trials":1172,"activeCount":74},[],{"trials":1174,"activeCount":74},[],{"trials":1176,"activeCount":74},[],{"intervention":955,"totalTrials":105,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1180,"activeCount":74},[],{"trials":1182,"activeCount":74},[],{"trials":1184,"activeCount":74},[1185],{"nctId":944,"briefTitle":945,"status":82,"phases":1186,"primaryCompletion":947,"completion":948,"start":949,"enrollment":950,"conditions":1187,"interventions":1188},[63],[952],[935,954,955],{"trials":1190,"activeCount":74},[],{"trials":1192,"activeCount":74},[],{"trials":1194,"activeCount":74},[],{"intervention":1196,"totalTrials":105,"cells":1197},"Ketamine Hydrochloride",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1199,"activeCount":74},[],{"trials":1201,"activeCount":74},[],{"trials":1203,"activeCount":74},[1204],{"nctId":1205,"briefTitle":1206,"status":123,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1208,"enrollment":74,"conditions":1209,"interventions":1210},"NCT06036511","Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD",[62,63],"2023-12-31",[190],[1196],{"trials":1212,"activeCount":74},[],{"trials":1214,"activeCount":74},[],{"trials":1216,"activeCount":74},[],{"intervention":1218,"totalTrials":105,"cells":1219},"Ropivacaine concentration",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1221,"activeCount":74},[],{"trials":1223,"activeCount":74},[],{"trials":1225,"activeCount":74},[1226],{"nctId":1227,"briefTitle":1228,"status":1025,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1235},"NCT01452126","Minimum Effective Concentration of Ropivacaine for Brachial Plexus Block Via the Supraclavicular and Infraclavicular Approach, Femoral Nerve Block, Sciatic Nerve Block Via the Popliteal and Parasacral Approach",[63],"2011-09","2011-06",49,[1234],"Surgical Anesthesia",[1218],{"trials":1237,"activeCount":74},[],{"trials":1239,"activeCount":74},[],{"trials":1241,"activeCount":74},[],{"intervention":1243,"totalTrials":105,"cells":1244},"Carboplatin",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1246,"activeCount":74},[],{"trials":1248,"activeCount":74},[],{"trials":1250,"activeCount":74},[1251],{"nctId":1252,"briefTitle":1253,"status":82,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1261},"NCT00277069","Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer",[62,63],"2005-03","2006-03","2000-05",33,[1260,15],"Breast",[1243,1262],"Vinorelbine",{"trials":1264,"activeCount":74},[],{"trials":1266,"activeCount":74},[],{"trials":1268,"activeCount":74},[],{"intervention":1262,"totalTrials":105,"cells":1270},{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1281,"PHASE4":1283,"NA":1285},{"trials":1272,"activeCount":74},[],{"trials":1274,"activeCount":74},[],{"trials":1276,"activeCount":74},[1277],{"nctId":1252,"briefTitle":1253,"status":82,"phases":1278,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":1279,"interventions":1280},[62,63],[1260,15],[1243,1262],{"trials":1282,"activeCount":74},[],{"trials":1284,"activeCount":74},[],{"trials":1286,"activeCount":74},[],{"intervention":1040,"totalTrials":105,"cells":1288},{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1299,"PHASE4":1301,"NA":1303},{"trials":1290,"activeCount":74},[],{"trials":1292,"activeCount":74},[],{"trials":1294,"activeCount":74},[1295],{"nctId":1033,"briefTitle":1034,"status":1025,"phases":1296,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":963,"conditions":1297,"interventions":1298},[63],[1030],[1014,1040],{"trials":1300,"activeCount":74},[],{"trials":1302,"activeCount":74},[],{"trials":1304,"activeCount":74},[],{"intervention":1306,"totalTrials":105,"cells":1307},"Convalescent Plasma",{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1309,"activeCount":74},[],{"trials":1311,"activeCount":74},[],{"trials":1313,"activeCount":74},[1314],{"nctId":1315,"briefTitle":1316,"status":82,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1323},"NCT04434131","Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19",[63],"2020-07-31","2021-03-12","2020-04-28",12,[1030],[1306],{"trials":1325,"activeCount":74},[],{"trials":1327,"activeCount":74},[],{"trials":1329,"activeCount":74},[],{"intervention":968,"totalTrials":105,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":74},[],{"trials":1335,"activeCount":74},[],{"trials":1337,"activeCount":74},[1338],{"nctId":957,"briefTitle":958,"status":82,"phases":1339,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":1340,"interventions":1341},[63],[965,966],[935,968],{"trials":1343,"activeCount":74},[],{"trials":1345,"activeCount":74},[],{"trials":1347,"activeCount":74},[],{"intervention":1349,"totalTrials":105,"cells":1350},"Liposomal 9-Nitrocamptothecin",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1352,"activeCount":74},[],{"trials":1354,"activeCount":74},[],{"trials":1356,"activeCount":74},[1357],{"nctId":1358,"briefTitle":1359,"status":82,"phases":1360,"primaryCompletion":1361,"completion":1361,"start":1362,"enrollment":9,"conditions":1363,"interventions":1364},"NCT00250068","Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)",[63],"2007-12","2003-04",[21,15],[1349],{"trials":1366,"activeCount":74},[],{"trials":1368,"activeCount":74},[],{"trials":1370,"activeCount":74},[],{"intervention":1372,"totalTrials":105,"cells":1373},"aldesleukin",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1375,"activeCount":74},[],{"trials":1377,"activeCount":74},[],{"trials":1379,"activeCount":74},[1380],{"nctId":1381,"briefTitle":1382,"status":82,"phases":1383,"primaryCompletion":1384,"completion":1104,"start":1385,"enrollment":1001,"conditions":1386,"interventions":1387},"NCT00003585","Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer",[62,63],"2001-08","1996-08",[1003],[1372,1388,1389,1390],"recombinant interferon alfa","fluorouracil","isotretinoin",{"trials":1392,"activeCount":74},[],{"trials":1394,"activeCount":74},[],{"trials":1396,"activeCount":74},[],{"intervention":1388,"totalTrials":105,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":74},[],{"trials":1402,"activeCount":74},[],{"trials":1404,"activeCount":74},[1405],{"nctId":1381,"briefTitle":1382,"status":82,"phases":1406,"primaryCompletion":1384,"completion":1104,"start":1385,"enrollment":1001,"conditions":1407,"interventions":1408},[62,63],[1003],[1372,1388,1389,1390],{"trials":1410,"activeCount":74},[],{"trials":1412,"activeCount":74},[],{"trials":1414,"activeCount":74},[],{"intervention":1389,"totalTrials":105,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":74},[],{"trials":1420,"activeCount":74},[],{"trials":1422,"activeCount":74},[1423],{"nctId":1381,"briefTitle":1382,"status":82,"phases":1424,"primaryCompletion":1384,"completion":1104,"start":1385,"enrollment":1001,"conditions":1425,"interventions":1426},[62,63],[1003],[1372,1388,1389,1390],{"trials":1428,"activeCount":74},[],{"trials":1430,"activeCount":74},[],{"trials":1432,"activeCount":74},[],{"intervention":1390,"totalTrials":105,"cells":1434},{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1436,"activeCount":74},[],{"trials":1438,"activeCount":74},[],{"trials":1440,"activeCount":74},[1441],{"nctId":1381,"briefTitle":1382,"status":82,"phases":1442,"primaryCompletion":1384,"completion":1104,"start":1385,"enrollment":1001,"conditions":1443,"interventions":1444},[62,63],[1003],[1372,1388,1389,1390],{"trials":1446,"activeCount":74},[],{"trials":1448,"activeCount":74},[],{"trials":1450,"activeCount":74},[],{"intervention":1452,"totalTrials":105,"cells":1453},"GW572016",{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1468,"PHASE4":1470,"NA":1472},{"trials":1455,"activeCount":74},[],{"trials":1457,"activeCount":74},[],{"trials":1459,"activeCount":74},[1460],{"nctId":1461,"briefTitle":1462,"status":123,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1464,"enrollment":74,"conditions":1465,"interventions":1467},"NCT00455039","INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients",[62,63],"2023-07-31",[1466],"Breast Cancer",[1452],{"trials":1469,"activeCount":74},[],{"trials":1471,"activeCount":74},[],{"trials":1473,"activeCount":74},[],{"intervention":1475,"totalTrials":105,"cells":1476},"L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1478,"activeCount":74},[],{"trials":1480,"activeCount":74},[],{"trials":1482,"activeCount":74},[1483],{"nctId":1484,"briefTitle":1485,"status":123,"phases":1486,"primaryCompletion":1487,"completion":1488,"start":1362,"enrollment":74,"conditions":1489,"interventions":1490},"NCT00250120","Pharmacology Study of Aerosolized Liposomal",[63],"2007-03","2007-08",[21,15],[1475],{"trials":1492,"activeCount":74},[],{"trials":1494,"activeCount":74},[],{"trials":1496,"activeCount":74},[],{"intervention":1498,"totalTrials":105,"cells":1499},"three times weekly Epo",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1501,"activeCount":74},[],{"trials":1503,"activeCount":74},[],{"trials":1505,"activeCount":74},[1506],{"nctId":1507,"briefTitle":1508,"status":82,"phases":1509,"primaryCompletion":880,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1515},"NCT01235923","Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants",[63],"2009-12","2006-04",20,[1514],"Preterm Infants",[1498,1516],"weekly Epo",{"trials":1518,"activeCount":74},[],{"trials":1520,"activeCount":74},[],{"trials":1522,"activeCount":74},[],{"intervention":1516,"totalTrials":105,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":74},[],{"trials":1528,"activeCount":74},[],{"trials":1530,"activeCount":74},[1531],{"nctId":1507,"briefTitle":1508,"status":82,"phases":1532,"primaryCompletion":880,"completion":1510,"start":1511,"enrollment":1512,"conditions":1533,"interventions":1534},[63],[1514],[1498,1516],{"trials":1536,"activeCount":74},[],{"trials":1538,"activeCount":74},[],{"trials":1540,"activeCount":74},[],{"intervention":1542,"totalTrials":105,"cells":1543},"Thalidomide, alpha interferon",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1545,"activeCount":74},[],{"trials":1547,"activeCount":74},[],{"trials":1549,"activeCount":74},[1550],{"nctId":1551,"briefTitle":1552,"status":82,"phases":1553,"primaryCompletion":1554,"completion":1256,"start":1555,"enrollment":1321,"conditions":1556,"interventions":1558},"NCT00250796","Trial of Thalidomide, a- Interferon +\u002F- Octreotide in Patients With Unresectable Hepatocellular Carcinoma",[63],"2006-01","2000-09",[1557,15],"Liver",[1542,1559],"Thalidomide, interferon, Octreotide",{"trials":1561,"activeCount":74},[],{"trials":1563,"activeCount":74},[],{"trials":1565,"activeCount":74},[],{"intervention":1559,"totalTrials":105,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":74},[],{"trials":1571,"activeCount":74},[],{"trials":1573,"activeCount":74},[1574],{"nctId":1551,"briefTitle":1552,"status":82,"phases":1575,"primaryCompletion":1554,"completion":1256,"start":1555,"enrollment":1321,"conditions":1576,"interventions":1577},[63],[1557,15],[1542,1559],{"trials":1579,"activeCount":74},[],{"trials":1581,"activeCount":74},[],{"trials":1583,"activeCount":74},[],{"intervention":1005,"totalTrials":105,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":74},[],{"trials":1589,"activeCount":74},[],{"trials":1591,"activeCount":74},[1592],{"nctId":996,"briefTitle":997,"status":82,"phases":1593,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1594,"interventions":1595},[63],[1003],[976,1005,1006],{"trials":1597,"activeCount":74},[],{"trials":1599,"activeCount":74},[],{"trials":1601,"activeCount":74},[],{"intervention":1006,"totalTrials":105,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":74},[],{"trials":1607,"activeCount":74},[],{"trials":1609,"activeCount":74},[1610],{"nctId":996,"briefTitle":997,"status":82,"phases":1611,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1612,"interventions":1613},[63],[1003],[976,1005,1006],{"trials":1615,"activeCount":74},[],{"trials":1617,"activeCount":74},[],{"trials":1619,"activeCount":74},[],{"intervention":1621,"totalTrials":105,"cells":1622},"Psilocybin assisted therapy",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1637,"PHASE4":1639,"NA":1641},{"trials":1624,"activeCount":74},[],{"trials":1626,"activeCount":74},[],{"trials":1628,"activeCount":74},[1629],{"nctId":1630,"briefTitle":1631,"status":123,"phases":1632,"primaryCompletion":1633,"completion":1633,"start":188,"enrollment":74,"conditions":1634,"interventions":1636},"NCT07484906","Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies",[63],"2029-08-31",[1635],"Suicidal Ideation",[1621],{"trials":1638,"activeCount":74},[],{"trials":1640,"activeCount":74},[],{"trials":1642,"activeCount":74},[],{"intervention":1644,"totalTrials":70,"cells":1645},"Topotecan",{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1669,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1647,"activeCount":74},[],{"trials":1649,"activeCount":74},[1650,1658],{"nctId":1651,"briefTitle":1652,"status":82,"phases":1653,"primaryCompletion":1654,"completion":1654,"start":1511,"enrollment":19,"conditions":1655,"interventions":1657},"NCT00322751","Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer",[62],"2009-11",[1656],"Lung Cancer",[1644],{"nctId":1659,"briefTitle":1660,"status":82,"phases":1661,"primaryCompletion":1662,"completion":651,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1667},"NCT00320983","Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer",[62],"2004-06","2002-03",11,[1666],"Cervical Cancer",[1644,1668],"Cisplatin",{"trials":1670,"activeCount":74},[],{"trials":1672,"activeCount":74},[],{"trials":1674,"activeCount":74},[],{"trials":1676,"activeCount":74},[],{"intervention":1678,"totalTrials":105,"cells":1679},"Ranibizumab",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1693,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1681,"activeCount":74},[],{"trials":1683,"activeCount":74},[1684],{"nctId":1685,"briefTitle":1686,"status":82,"phases":1687,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":19,"conditions":1690,"interventions":1692},"NCT01169909","Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia",[62],"2014-07","2010-08",[1691],"Pterygium",[1678],{"trials":1694,"activeCount":74},[],{"trials":1696,"activeCount":74},[],{"trials":1698,"activeCount":74},[],{"trials":1700,"activeCount":74},[],{"intervention":1702,"totalTrials":105,"cells":1703},"Irinotecan",{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1705,"activeCount":74},[],{"trials":1707,"activeCount":74},[1708],{"nctId":1709,"briefTitle":1710,"status":82,"phases":1711,"primaryCompletion":949,"completion":949,"start":1712,"enrollment":19,"conditions":1713,"interventions":1715},"NCT00251797","A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors",[62],"2000-03",[1714,15],"Brain and Nervous System",[1702,1716],"Thalidomide",{"trials":1718,"activeCount":74},[],{"trials":1720,"activeCount":74},[],{"trials":1722,"activeCount":74},[],{"trials":1724,"activeCount":74},[],{"intervention":1716,"totalTrials":105,"cells":1726},{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1728,"activeCount":74},[],{"trials":1730,"activeCount":74},[1731],{"nctId":1709,"briefTitle":1710,"status":82,"phases":1732,"primaryCompletion":949,"completion":949,"start":1712,"enrollment":19,"conditions":1733,"interventions":1734},[62],[1714,15],[1702,1716],{"trials":1736,"activeCount":74},[],{"trials":1738,"activeCount":74},[],{"trials":1740,"activeCount":74},[],{"trials":1742,"activeCount":74},[],{"intervention":992,"totalTrials":105,"cells":1744},{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1753,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1746,"activeCount":74},[],{"trials":1748,"activeCount":74},[1749],{"nctId":983,"briefTitle":984,"status":82,"phases":1750,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":1751,"interventions":1752},[62],[990],[992,976],{"trials":1754,"activeCount":74},[],{"trials":1756,"activeCount":74},[],{"trials":1758,"activeCount":74},[],{"trials":1760,"activeCount":74},[],{"intervention":1668,"totalTrials":105,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1771,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1764,"activeCount":74},[],{"trials":1766,"activeCount":74},[1767],{"nctId":1659,"briefTitle":1660,"status":82,"phases":1768,"primaryCompletion":1662,"completion":651,"start":1663,"enrollment":1664,"conditions":1769,"interventions":1770},[62],[1666],[1644,1668],{"trials":1772,"activeCount":74},[],{"trials":1774,"activeCount":74},[],{"trials":1776,"activeCount":74},[],{"trials":1778,"activeCount":74},[],{"intervention":1780,"totalTrials":105,"cells":1781},"Ferumoxides 11.2Mg Solution for",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1783,"activeCount":74},[],{"trials":1785,"activeCount":74},[1786],{"nctId":1787,"briefTitle":1788,"status":82,"phases":1789,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1321,"conditions":1792,"interventions":1794},"NCT05959590","Ferumoxytol-enhanced Imaging of Osteomyelitis",[62],"2019-08-12","2014-02-12",[1793],"Osteomyelitis",[1780],{"trials":1796,"activeCount":74},[],{"trials":1798,"activeCount":74},[],{"trials":1800,"activeCount":74},[],{"trials":1802,"activeCount":74},[],{"intervention":1804,"totalTrials":105,"cells":1805},"Cannabidiol vaginal suppository",{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1807,"activeCount":74},[],{"trials":1809,"activeCount":74},[1810],{"nctId":1811,"briefTitle":1812,"status":123,"phases":1813,"primaryCompletion":1814,"completion":1815,"start":1816,"enrollment":74,"conditions":1817,"interventions":1820},"NCT04349930","The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)",[62],"2022-07","2022-09","2021-01",[1818,1819],"Interstitial Cystitis","Bladder Pain Syndrome",[1804],{"trials":1822,"activeCount":74},[],{"trials":1824,"activeCount":74},[],{"trials":1826,"activeCount":74},[],{"trials":1828,"activeCount":74},[],{"intervention":1830,"totalTrials":105,"cells":1831},"Ibuprofen 600 mg",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1844,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1833,"activeCount":74},[],{"trials":1835,"activeCount":74},[1836],{"nctId":1837,"briefTitle":1838,"status":82,"phases":1839,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":1321,"conditions":1842,"interventions":1843},"NCT06247462","Ibuprofen and Biomarkers of Acute Kidney Injury After Running in the Heat",[62],"2023-09-05","2023-06-01",[1132],[1830],{"trials":1845,"activeCount":74},[],{"trials":1847,"activeCount":74},[],{"trials":1849,"activeCount":74},[],{"trials":1851,"activeCount":74},[],{"intervention":1853,"totalTrials":105,"cells":1854},"Capecitabine in Combination with Cisplatin and Irinotecan",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1868,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1856,"activeCount":74},[],{"trials":1858,"activeCount":74},[1859],{"nctId":1860,"briefTitle":1861,"status":82,"phases":1862,"primaryCompletion":1488,"completion":1863,"start":1362,"enrollment":1864,"conditions":1865,"interventions":1867},"NCT00249977","Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan",[62],"2009-01",21,[1866,15],"Solid Tumors",[1853],{"trials":1869,"activeCount":74},[],{"trials":1871,"activeCount":74},[],{"trials":1873,"activeCount":74},[],{"trials":1875,"activeCount":74},[],{"intervention":1877,"totalTrials":105,"cells":1878},"Amiloride",{"EARLY_PHASE1":1879,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1880,"activeCount":74},[1881],{"nctId":1882,"briefTitle":1883,"status":1025,"phases":1884,"primaryCompletion":1885,"completion":1885,"start":1886,"enrollment":1887,"conditions":1888,"interventions":1892},"NCT01804777","Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes",[61],"2014-12","2013-03",9,[1889,1890,1891],"Proteinuria","Hypertension","Type II Diabetes",[1877,1893],"HCTZ",{"trials":1895,"activeCount":74},[],{"trials":1897,"activeCount":74},[],{"trials":1899,"activeCount":74},[],{"trials":1901,"activeCount":74},[],{"trials":1903,"activeCount":74},[],{"intervention":1893,"totalTrials":105,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1907,"activeCount":74},[1908],{"nctId":1882,"briefTitle":1883,"status":1025,"phases":1909,"primaryCompletion":1885,"completion":1885,"start":1886,"enrollment":1887,"conditions":1910,"interventions":1911},[61],[1889,1890,1891],[1877,1893],{"trials":1913,"activeCount":74},[],{"trials":1915,"activeCount":74},[],{"trials":1917,"activeCount":74},[],{"trials":1919,"activeCount":74},[],{"trials":1921,"activeCount":74},[],{"intervention":1923,"totalTrials":105,"cells":1924},"Curcumin Pill",{"EARLY_PHASE1":1925,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1926,"activeCount":74},[1927],{"nctId":1928,"briefTitle":1929,"status":123,"phases":1930,"primaryCompletion":1931,"completion":1931,"start":1932,"enrollment":74,"conditions":1933,"interventions":1935},"NCT03845322","Curcumin\u002FTurmeric as a Treatment for Patients With Subdural Hematomas Recurrence",[61],"2020-02-26","2018-12-18",[1934],"Hematoma, Subdural, Chronic",[1923],{"trials":1937,"activeCount":74},[],{"trials":1939,"activeCount":74},[],{"trials":1941,"activeCount":74},[],{"trials":1943,"activeCount":74},[],{"trials":1945,"activeCount":74},[],{"intervention":1947,"totalTrials":105,"cells":1948},"Testosterone",{"EARLY_PHASE1":1949,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1950,"activeCount":74},[1951],{"nctId":1952,"briefTitle":1953,"status":82,"phases":1954,"primaryCompletion":1955,"completion":1955,"start":1956,"enrollment":1512,"conditions":1957,"interventions":1959},"NCT05781685","The Influence of Testosterone on Experimental Pain Perception",[61],"2018-07-17","2017-10-01",[1958],"Acute Pain",[1947],{"trials":1961,"activeCount":74},[],{"trials":1963,"activeCount":74},[],{"trials":1965,"activeCount":74},[],{"trials":1967,"activeCount":74},[],{"trials":1969,"activeCount":74},[],{"intervention":1971,"totalTrials":105,"cells":1972},"Alcohol beverage",{"EARLY_PHASE1":1973,"PHASE1":1986,"PHASE2":1988,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1974,"activeCount":74},[1975],{"nctId":1976,"briefTitle":1977,"status":82,"phases":1978,"primaryCompletion":1979,"completion":1979,"start":1980,"enrollment":1981,"conditions":1982,"interventions":1985},"NCT03037749","Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence",[61],"2018-08-31","2015-09-27",42,[1983,1984],"Domestic Violence","Alcohol Consumption",[1971],{"trials":1987,"activeCount":74},[],{"trials":1989,"activeCount":74},[],{"trials":1991,"activeCount":74},[],{"trials":1993,"activeCount":74},[],{"trials":1995,"activeCount":74},[],{"intervention":1997,"totalTrials":105,"cells":1998},"Simvastatin",{"EARLY_PHASE1":1999,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2019},{"trials":2000,"activeCount":74},[2001],{"nctId":2002,"briefTitle":2003,"status":1025,"phases":2004,"primaryCompletion":1129,"completion":1129,"start":2005,"enrollment":1321,"conditions":2006,"interventions":2010},"NCT01764451","Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins",[61],"2012-03",[2007,2008,2009],"Cavernous Angioma, Familial","Cerebral Cavernous Malformations","Cerebral Cavernous Hemangioma",[1997],{"trials":2012,"activeCount":74},[],{"trials":2014,"activeCount":74},[],{"trials":2016,"activeCount":74},[],{"trials":2018,"activeCount":74},[],{"trials":2020,"activeCount":74},[],{"intervention":2022,"totalTrials":105,"cells":2023},"Memantine Hydrochloride",{"EARLY_PHASE1":2024,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2025,"activeCount":74},[2026],{"nctId":2027,"briefTitle":2028,"status":123,"phases":2029,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":74,"conditions":2032,"interventions":2034},"NCT04966546","Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)",[61],"2025-12-01","2022-06-01",[2033],"Chronic Subdural Hematoma",[2022],{"trials":2036,"activeCount":74},[],{"trials":2038,"activeCount":74},[],{"trials":2040,"activeCount":74},[],{"trials":2042,"activeCount":74},[],{"trials":2044,"activeCount":74},[],{"intervention":2046,"totalTrials":105,"cells":2047},"Ixekizumab Auto-Injector",{"EARLY_PHASE1":2048,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2049,"activeCount":74},[2050],{"nctId":2051,"briefTitle":2052,"status":82,"phases":2053,"primaryCompletion":2054,"completion":2054,"start":2055,"enrollment":1887,"conditions":2056,"interventions":2060},"NCT05030415","Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris",[61],"2024-03-25","2021-08-12",[2057,2058,2059],"Lichen Planus Scalp","Lichen Planus","Lichen Planopilaris",[2046],{"trials":2062,"activeCount":74},[],{"trials":2064,"activeCount":74},[],{"trials":2066,"activeCount":74},[],{"trials":2068,"activeCount":74},[],{"trials":2070,"activeCount":74},[],{"intervention":2072,"totalTrials":105,"cells":2073},"Cannabidiol Oil",{"EARLY_PHASE1":2074,"PHASE1":2084,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2075,"activeCount":74},[2076],{"nctId":2077,"briefTitle":2078,"status":123,"phases":2079,"primaryCompletion":2080,"completion":2080,"start":2080,"enrollment":74,"conditions":2081,"interventions":2083},"NCT05044936","Topical Cannabidiol Cream and Post-exercise Recovery",[61],"2023-05-15",[2082],"Muscle Damage",[2072],{"trials":2085,"activeCount":74},[],{"trials":2087,"activeCount":74},[],{"trials":2089,"activeCount":74},[],{"trials":2091,"activeCount":74},[],{"trials":2093,"activeCount":74},[],{"intervention":2095,"totalTrials":105,"cells":2096},"Pramipexole Oral",{"EARLY_PHASE1":2097,"PHASE1":2108,"PHASE2":2110,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2098,"activeCount":74},[2099],{"nctId":2100,"briefTitle":2101,"status":82,"phases":2102,"primaryCompletion":2103,"completion":2104,"start":2105,"enrollment":652,"conditions":2106,"interventions":2107},"NCT03842709","Non-Opioid Pramipexole and Pain",[61],"2020-01-31","2021-02-15","2019-05-01",[23],[2095],{"trials":2109,"activeCount":74},[],{"trials":2111,"activeCount":74},[],{"trials":2113,"activeCount":74},[],{"trials":2115,"activeCount":74},[],{"trials":2117,"activeCount":74},[],{"intervention":2119,"totalTrials":2120,"cells":2121},"Ketamine",3,{"EARLY_PHASE1":2122,"PHASE1":2136,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2123,"activeCount":74},[2124],{"nctId":2125,"briefTitle":2126,"status":82,"phases":2127,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1664,"conditions":2130,"interventions":2134},"NCT04022226","EEG Characteristics in ECT",[61],"2020-10-01","2019-10-01",[2131,2132,2119,2133],"Electroconvulsive Therapy","Direct Current Electroencephalogram","Spreadind Depression",[2119,2135],"Methohexital",{"trials":2137,"activeCount":74},[2138],{"nctId":2139,"briefTitle":2140,"status":82,"phases":2141,"primaryCompletion":2142,"completion":2143,"start":2144,"enrollment":19,"conditions":2145,"interventions":2149},"NCT02501941","Spreading Depolarization and Ketamine Suppression",[62],"2017-01-01","2017-05-01","2015-07",[2146,2147,2148,30],"Cortical Spreading Depolarization","Cortical Spreading Depression","Subarachoid Hemorrhage",[2150],"ketamine",{"trials":2152,"activeCount":74},[],{"trials":2154,"activeCount":74},[],{"trials":2156,"activeCount":74},[],{"trials":2158,"activeCount":74},[2159],{"nctId":2160,"briefTitle":2161,"status":82,"phases":2162,"primaryCompletion":1886,"completion":1886,"start":2163,"enrollment":1512,"conditions":2164,"interventions":2167},"NCT01567852","Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time",[66],"2011-08",[2165,2166],"Post-anesthesia Recovery","Orientation",[2119,2135],{"intervention":2169,"totalTrials":70,"cells":2170},"metformin",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2177,"PHASE4":2191,"NA":2193},{"trials":2172,"activeCount":74},[],{"trials":2174,"activeCount":74},[],{"trials":2176,"activeCount":74},[],{"trials":2178,"activeCount":74},[2179],{"nctId":2180,"briefTitle":2181,"status":82,"phases":2182,"primaryCompletion":2183,"completion":2183,"start":2184,"enrollment":2185,"conditions":2186,"interventions":2189},"NCT03309007","A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes",[64],"2020-08-20","2017-09-01",25,[2187,2188],"PreDiabetes","Aging",[2190],"Metformin",{"trials":2192,"activeCount":74},[],{"trials":2194,"activeCount":74},[2195],{"nctId":2196,"briefTitle":2197,"status":82,"phases":2198,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2205},"NCT00965991","Metformin Compared to Glyburide in Gestational Diabetes",[66],"2008-05","2023-08","2003-07",149,[2204],"Gestational Diabetes",[2169,2206],"Glyburide",{"intervention":410,"totalTrials":70,"cells":2208},{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2217,"NA":2223},{"trials":2210,"activeCount":74},[],{"trials":2212,"activeCount":74},[],{"trials":2214,"activeCount":74},[],{"trials":2216,"activeCount":74},[],{"trials":2218,"activeCount":74},[2219],{"nctId":402,"briefTitle":403,"status":123,"phases":2220,"primaryCompletion":405,"completion":405,"start":406,"enrollment":74,"conditions":2221,"interventions":2222},[65],[408],[389,410],{"trials":2224,"activeCount":74},[2225],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2228,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2231,"interventions":2233},"NCT02893371","Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies",[],"2019-06-30",1037352,[2232],"Bipolar Disorder",[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],"Lithium Carbonate","Lamotrigine","Valproic Acid","Oxcarbazepine","Carbamazepine","Ziprasidone","Quetiapine","Olanzapine","Aripiprazole","Fluoxetine \u002F Olanzapine","Haloperidol","Perphenazine","Clozapine","Asenapine","Lurasidone","Paliperidone","Mirtazapine","Bupropion","Desvenlafaxine","Duloxetine","Venlafaxine","Citalopram","Escitalopram","Fluoxetine","Fluvoxamine","Paroxetine","Sertraline","Vilazodone","Doxepin",{"intervention":2264,"totalTrials":70,"cells":2265},"9-NC in aerosol reservoir",{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2270,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2267,"activeCount":74},[],{"trials":2269,"activeCount":74},[],{"trials":2271,"activeCount":74},[2272],{"nctId":2273,"briefTitle":2274,"status":82,"phases":2275,"primaryCompletion":2276,"completion":650,"start":1362,"enrollment":2277,"conditions":2278,"interventions":2281},"NCT00249990","Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)",[63],"2006-07",39,[2279,2280],"Corpus Uteri","Endometrial Cancer",[2264],{"trials":2283,"activeCount":74},[],{"trials":2285,"activeCount":74},[],{"trials":2287,"activeCount":74},[2288],{"nctId":2289,"briefTitle":2290,"status":82,"phases":2291,"completion":305,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2295},"NCT00277082","Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung",[],"2003-08",24,[2279,1656],[2264],{"intervention":2135,"totalTrials":70,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2299,"activeCount":74},[2300],{"nctId":2125,"briefTitle":2126,"status":82,"phases":2301,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1664,"conditions":2302,"interventions":2303},[61],[2131,2132,2119,2133],[2119,2135],{"trials":2305,"activeCount":74},[],{"trials":2307,"activeCount":74},[],{"trials":2309,"activeCount":74},[],{"trials":2311,"activeCount":74},[],{"trials":2313,"activeCount":74},[2314],{"nctId":2160,"briefTitle":2161,"status":82,"phases":2315,"primaryCompletion":1886,"completion":1886,"start":2163,"enrollment":1512,"conditions":2316,"interventions":2317},[66],[2165,2166],[2119,2135],{"intervention":2319,"totalTrials":105,"cells":2320},"Treatment of Furosemide + Hydrochlorothiazide",{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2331},{"trials":2322,"activeCount":74},[],{"trials":2324,"activeCount":74},[],{"trials":2326,"activeCount":74},[],{"trials":2328,"activeCount":74},[],{"trials":2330,"activeCount":74},[],{"trials":2332,"activeCount":74},[2333],{"nctId":2334,"briefTitle":2335,"status":82,"phases":2336,"primaryCompletion":2337,"completion":2337,"start":2338,"enrollment":9,"conditions":2339,"interventions":2341},"NCT00690521","A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients",[66],"2009-11-10","2004-10-26",[2340],"Congestive Heart Failure",[2319,2342],"Treatment of Furosemide + Metolazone",{"intervention":2342,"totalTrials":105,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2346,"activeCount":74},[],{"trials":2348,"activeCount":74},[],{"trials":2350,"activeCount":74},[],{"trials":2352,"activeCount":74},[],{"trials":2354,"activeCount":74},[],{"trials":2356,"activeCount":74},[2357],{"nctId":2334,"briefTitle":2335,"status":82,"phases":2358,"primaryCompletion":2337,"completion":2337,"start":2338,"enrollment":9,"conditions":2359,"interventions":2360},[66],[2340],[2319,2342],{"intervention":2362,"totalTrials":105,"cells":2363},"Amlodipine and Hydrocholorothiazide",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2374},{"trials":2365,"activeCount":74},[],{"trials":2367,"activeCount":74},[],{"trials":2369,"activeCount":74},[],{"trials":2371,"activeCount":74},[],{"trials":2373,"activeCount":74},[],{"trials":2375,"activeCount":74},[2376],{"nctId":2377,"briefTitle":2378,"status":123,"phases":2379,"primaryCompletion":2380,"completion":2380,"start":1103,"enrollment":74,"conditions":2381,"interventions":2382},"NCT00656331","The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.",[66],"2012-06",[1890],[2362],{"intervention":2206,"totalTrials":105,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2386,"activeCount":74},[],{"trials":2388,"activeCount":74},[],{"trials":2390,"activeCount":74},[],{"trials":2392,"activeCount":74},[],{"trials":2394,"activeCount":74},[],{"trials":2396,"activeCount":74},[2397],{"nctId":2196,"briefTitle":2197,"status":82,"phases":2398,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":2399,"interventions":2400},[66],[2204],[2169,2206],{"intervention":2402,"totalTrials":105,"cells":2403},"Nitrous Oxide",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2405,"activeCount":74},[],{"trials":2407,"activeCount":74},[],{"trials":2409,"activeCount":74},[],{"trials":2411,"activeCount":74},[],{"trials":2413,"activeCount":74},[],{"trials":2415,"activeCount":74},[2416],{"nctId":2417,"briefTitle":2418,"status":82,"phases":2419,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":2277,"conditions":2422,"interventions":2424},"NCT02755090","Nitrous Oxide Versus Intravenous Sedation for Anesthesia",[66],"2017-05","2016-07",[2423],"Pregnancy Termination in Second Trimester",[2402,2425],"IV Saline",{"intervention":2425,"totalTrials":105,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2429,"activeCount":74},[],{"trials":2431,"activeCount":74},[],{"trials":2433,"activeCount":74},[],{"trials":2435,"activeCount":74},[],{"trials":2437,"activeCount":74},[],{"trials":2439,"activeCount":74},[2440],{"nctId":2417,"briefTitle":2418,"status":82,"phases":2441,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":2277,"conditions":2442,"interventions":2443},[66],[2423],[2402,2425],{"intervention":2445,"totalTrials":105,"cells":2446},"Anticholinergic medications",{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2451,"PHASE3":2453,"PHASE4":2455,"NA":2457},{"trials":2448,"activeCount":74},[],{"trials":2450,"activeCount":74},[],{"trials":2452,"activeCount":74},[],{"trials":2454,"activeCount":74},[],{"trials":2456,"activeCount":74},[],{"trials":2458,"activeCount":74},[2459],{"nctId":2460,"briefTitle":2461,"status":82,"phases":2462,"primaryCompletion":2463,"completion":2463,"start":2464,"enrollment":2465,"conditions":2466,"interventions":2468},"NCT01829425","Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy",[66],"2017-10-27","2013-04-22",165,[2467],"Urinary Incontinence, Urge",[2445],{"intervention":2470,"totalTrials":105,"cells":2471},"Tissue Repository",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2473,"activeCount":74},[],{"trials":2475,"activeCount":74},[],{"trials":2477,"activeCount":74},[],{"trials":2479,"activeCount":74},[],{"trials":2481,"activeCount":74},[],{"trials":2483,"activeCount":74},[2484],{"nctId":2485,"briefTitle":2486,"status":123,"phases":2487,"primaryCompletion":651,"completion":651,"start":651,"enrollment":74,"conditions":2488,"interventions":2490},"NCT00298064","Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer",[66],[1666,2489],"Cervix",[2470],{"intervention":2492,"totalTrials":105,"cells":2493},"Antihypertensive Agents",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2502,"NA":2504},{"trials":2495,"activeCount":74},[],{"trials":2497,"activeCount":74},[],{"trials":2499,"activeCount":74},[],{"trials":2501,"activeCount":74},[],{"trials":2503,"activeCount":74},[],{"trials":2505,"activeCount":74},[2506],{"nctId":2507,"briefTitle":2508,"status":82,"phases":2509,"primaryCompletion":1129,"completion":2510,"start":85,"enrollment":2511,"conditions":2512,"interventions":2516},"NCT01421771","Blood Pressure in Dialysis Patients",[66],"2016-06",126,[1890,2513,2514,2515],"Renal Failure Chronic Requiring Hemodialysis","Blood Pressure","Dialysis",[2492],{"intervention":2234,"totalTrials":105,"cells":2518},{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2520,"activeCount":74},[],{"trials":2522,"activeCount":74},[],{"trials":2524,"activeCount":74},[],{"trials":2526,"activeCount":74},[],{"trials":2528,"activeCount":74},[],{"trials":2530,"activeCount":74},[2531],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2532,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2533,"interventions":2534},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2235,"totalTrials":105,"cells":2536},{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2538,"activeCount":74},[],{"trials":2540,"activeCount":74},[],{"trials":2542,"activeCount":74},[],{"trials":2544,"activeCount":74},[],{"trials":2546,"activeCount":74},[],{"trials":2548,"activeCount":74},[2549],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2550,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2551,"interventions":2552},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2236,"totalTrials":105,"cells":2554},{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2561,"PHASE4":2563,"NA":2565},{"trials":2556,"activeCount":74},[],{"trials":2558,"activeCount":74},[],{"trials":2560,"activeCount":74},[],{"trials":2562,"activeCount":74},[],{"trials":2564,"activeCount":74},[],{"trials":2566,"activeCount":74},[2567],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2568,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2569,"interventions":2570},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2237,"totalTrials":105,"cells":2572},{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2574,"activeCount":74},[],{"trials":2576,"activeCount":74},[],{"trials":2578,"activeCount":74},[],{"trials":2580,"activeCount":74},[],{"trials":2582,"activeCount":74},[],{"trials":2584,"activeCount":74},[2585],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2586,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2587,"interventions":2588},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2238,"totalTrials":105,"cells":2590},{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2595,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2592,"activeCount":74},[],{"trials":2594,"activeCount":74},[],{"trials":2596,"activeCount":74},[],{"trials":2598,"activeCount":74},[],{"trials":2600,"activeCount":74},[],{"trials":2602,"activeCount":74},[2603],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2604,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2605,"interventions":2606},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2239,"totalTrials":105,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2610,"activeCount":74},[],{"trials":2612,"activeCount":74},[],{"trials":2614,"activeCount":74},[],{"trials":2616,"activeCount":74},[],{"trials":2618,"activeCount":74},[],{"trials":2620,"activeCount":74},[2621],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2622,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2623,"interventions":2624},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2240,"totalTrials":105,"cells":2626},{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2628,"activeCount":74},[],{"trials":2630,"activeCount":74},[],{"trials":2632,"activeCount":74},[],{"trials":2634,"activeCount":74},[],{"trials":2636,"activeCount":74},[],{"trials":2638,"activeCount":74},[2639],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2640,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2641,"interventions":2642},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2241,"totalTrials":105,"cells":2644},{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2646,"activeCount":74},[],{"trials":2648,"activeCount":74},[],{"trials":2650,"activeCount":74},[],{"trials":2652,"activeCount":74},[],{"trials":2654,"activeCount":74},[],{"trials":2656,"activeCount":74},[2657],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2658,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2659,"interventions":2660},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2242,"totalTrials":105,"cells":2662},{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2664,"activeCount":74},[],{"trials":2666,"activeCount":74},[],{"trials":2668,"activeCount":74},[],{"trials":2670,"activeCount":74},[],{"trials":2672,"activeCount":74},[],{"trials":2674,"activeCount":74},[2675],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2676,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2677,"interventions":2678},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2243,"totalTrials":105,"cells":2680},{"EARLY_PHASE1":2681,"PHASE1":2683,"PHASE2":2685,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2682,"activeCount":74},[],{"trials":2684,"activeCount":74},[],{"trials":2686,"activeCount":74},[],{"trials":2688,"activeCount":74},[],{"trials":2690,"activeCount":74},[],{"trials":2692,"activeCount":74},[2693],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2694,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2695,"interventions":2696},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2244,"totalTrials":105,"cells":2698},{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2700,"activeCount":74},[],{"trials":2702,"activeCount":74},[],{"trials":2704,"activeCount":74},[],{"trials":2706,"activeCount":74},[],{"trials":2708,"activeCount":74},[],{"trials":2710,"activeCount":74},[2711],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2712,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2713,"interventions":2714},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2245,"totalTrials":105,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2723,"PHASE4":2725,"NA":2727},{"trials":2718,"activeCount":74},[],{"trials":2720,"activeCount":74},[],{"trials":2722,"activeCount":74},[],{"trials":2724,"activeCount":74},[],{"trials":2726,"activeCount":74},[],{"trials":2728,"activeCount":74},[2729],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2730,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2731,"interventions":2732},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2246,"totalTrials":105,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2736,"activeCount":74},[],{"trials":2738,"activeCount":74},[],{"trials":2740,"activeCount":74},[],{"trials":2742,"activeCount":74},[],{"trials":2744,"activeCount":74},[],{"trials":2746,"activeCount":74},[2747],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2748,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2749,"interventions":2750},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2247,"totalTrials":105,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2754,"activeCount":74},[],{"trials":2756,"activeCount":74},[],{"trials":2758,"activeCount":74},[],{"trials":2760,"activeCount":74},[],{"trials":2762,"activeCount":74},[],{"trials":2764,"activeCount":74},[2765],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2766,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2767,"interventions":2768},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2248,"totalTrials":105,"cells":2770},{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2775,"PHASE3":2777,"PHASE4":2779,"NA":2781},{"trials":2772,"activeCount":74},[],{"trials":2774,"activeCount":74},[],{"trials":2776,"activeCount":74},[],{"trials":2778,"activeCount":74},[],{"trials":2780,"activeCount":74},[],{"trials":2782,"activeCount":74},[2783],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2784,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2785,"interventions":2786},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2249,"totalTrials":105,"cells":2788},{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2793,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2790,"activeCount":74},[],{"trials":2792,"activeCount":74},[],{"trials":2794,"activeCount":74},[],{"trials":2796,"activeCount":74},[],{"trials":2798,"activeCount":74},[],{"trials":2800,"activeCount":74},[2801],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2802,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2803,"interventions":2804},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2250,"totalTrials":105,"cells":2806},{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2811,"PHASE3":2813,"PHASE4":2815,"NA":2817},{"trials":2808,"activeCount":74},[],{"trials":2810,"activeCount":74},[],{"trials":2812,"activeCount":74},[],{"trials":2814,"activeCount":74},[],{"trials":2816,"activeCount":74},[],{"trials":2818,"activeCount":74},[2819],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2820,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2821,"interventions":2822},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2251,"totalTrials":105,"cells":2824},{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2826,"activeCount":74},[],{"trials":2828,"activeCount":74},[],{"trials":2830,"activeCount":74},[],{"trials":2832,"activeCount":74},[],{"trials":2834,"activeCount":74},[],{"trials":2836,"activeCount":74},[2837],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2838,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2839,"interventions":2840},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2252,"totalTrials":105,"cells":2842},{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2849,"PHASE4":2851,"NA":2853},{"trials":2844,"activeCount":74},[],{"trials":2846,"activeCount":74},[],{"trials":2848,"activeCount":74},[],{"trials":2850,"activeCount":74},[],{"trials":2852,"activeCount":74},[],{"trials":2854,"activeCount":74},[2855],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2856,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2857,"interventions":2858},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2253,"totalTrials":105,"cells":2860},{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2862,"activeCount":74},[],{"trials":2864,"activeCount":74},[],{"trials":2866,"activeCount":74},[],{"trials":2868,"activeCount":74},[],{"trials":2870,"activeCount":74},[],{"trials":2872,"activeCount":74},[2873],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2874,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2875,"interventions":2876},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2254,"totalTrials":105,"cells":2878},{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2887,"NA":2889},{"trials":2880,"activeCount":74},[],{"trials":2882,"activeCount":74},[],{"trials":2884,"activeCount":74},[],{"trials":2886,"activeCount":74},[],{"trials":2888,"activeCount":74},[],{"trials":2890,"activeCount":74},[2891],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2892,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2893,"interventions":2894},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2255,"totalTrials":105,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2903,"PHASE4":2905,"NA":2907},{"trials":2898,"activeCount":74},[],{"trials":2900,"activeCount":74},[],{"trials":2902,"activeCount":74},[],{"trials":2904,"activeCount":74},[],{"trials":2906,"activeCount":74},[],{"trials":2908,"activeCount":74},[2909],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2910,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2911,"interventions":2912},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2256,"totalTrials":105,"cells":2914},{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2921,"PHASE4":2923,"NA":2925},{"trials":2916,"activeCount":74},[],{"trials":2918,"activeCount":74},[],{"trials":2920,"activeCount":74},[],{"trials":2922,"activeCount":74},[],{"trials":2924,"activeCount":74},[],{"trials":2926,"activeCount":74},[2927],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2928,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2929,"interventions":2930},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2257,"totalTrials":105,"cells":2932},{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2934,"activeCount":74},[],{"trials":2936,"activeCount":74},[],{"trials":2938,"activeCount":74},[],{"trials":2940,"activeCount":74},[],{"trials":2942,"activeCount":74},[],{"trials":2944,"activeCount":74},[2945],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2946,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2947,"interventions":2948},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2258,"totalTrials":105,"cells":2950},{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2957,"PHASE4":2959,"NA":2961},{"trials":2952,"activeCount":74},[],{"trials":2954,"activeCount":74},[],{"trials":2956,"activeCount":74},[],{"trials":2958,"activeCount":74},[],{"trials":2960,"activeCount":74},[],{"trials":2962,"activeCount":74},[2963],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2964,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2965,"interventions":2966},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2259,"totalTrials":105,"cells":2968},{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2977,"NA":2979},{"trials":2970,"activeCount":74},[],{"trials":2972,"activeCount":74},[],{"trials":2974,"activeCount":74},[],{"trials":2976,"activeCount":74},[],{"trials":2978,"activeCount":74},[],{"trials":2980,"activeCount":74},[2981],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":2982,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":2983,"interventions":2984},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2260,"totalTrials":105,"cells":2986},{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":2995,"NA":2997},{"trials":2988,"activeCount":74},[],{"trials":2990,"activeCount":74},[],{"trials":2992,"activeCount":74},[],{"trials":2994,"activeCount":74},[],{"trials":2996,"activeCount":74},[],{"trials":2998,"activeCount":74},[2999],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":3000,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":3001,"interventions":3002},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2261,"totalTrials":105,"cells":3004},{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":3006,"activeCount":74},[],{"trials":3008,"activeCount":74},[],{"trials":3010,"activeCount":74},[],{"trials":3012,"activeCount":74},[],{"trials":3014,"activeCount":74},[],{"trials":3016,"activeCount":74},[3017],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":3018,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":3019,"interventions":3020},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":2262,"totalTrials":105,"cells":3022},{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3029,"PHASE4":3031,"NA":3033},{"trials":3024,"activeCount":74},[],{"trials":3026,"activeCount":74},[],{"trials":3028,"activeCount":74},[],{"trials":3030,"activeCount":74},[],{"trials":3032,"activeCount":74},[],{"trials":3034,"activeCount":74},[3035],{"nctId":2226,"briefTitle":2227,"status":1025,"phases":3036,"primaryCompletion":2229,"completion":2229,"start":606,"enrollment":2230,"conditions":3037,"interventions":3038},[],[2232],[2234,2235,2236,2237,2238,2239,410,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262],{"intervention":3040,"totalTrials":105,"cells":3041},"Tranexamic Acid",{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3043,"activeCount":74},[],{"trials":3045,"activeCount":74},[],{"trials":3047,"activeCount":74},[],{"trials":3049,"activeCount":74},[],{"trials":3051,"activeCount":74},[],{"trials":3053,"activeCount":74},[3054],{"nctId":3055,"briefTitle":3056,"status":82,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":2185,"conditions":3060,"interventions":3062},"NCT02867163","Tranexamic Acid and Blood Clots in Knee Surgery",[],"2017-11-08","2017-05-16",[3061],"Venous Thrombosis",[3040],{"intervention":3064,"totalTrials":105,"cells":3065},"pamidronate",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3067,"activeCount":74},[],{"trials":3069,"activeCount":74},[],{"trials":3071,"activeCount":74},[],{"trials":3073,"activeCount":74},[],{"trials":3075,"activeCount":74},[],{"trials":3077,"activeCount":74},[3078],{"nctId":3079,"briefTitle":3080,"status":82,"phases":3081,"primaryCompletion":2163,"completion":2163,"start":650,"enrollment":2293,"conditions":3082,"interventions":3088},"NCT00655681","Prevention of Post Operative Bone Loss in Children",[66],[3083,3084,3085,3086,3087],"Osteoporosis","Cerebral Palsy","Spina Bifida","Osteopenia","Osteogenesis Imperfecta",[3064],{"intervention":3090,"totalTrials":105,"cells":3091},"Insulin Detemir",{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3098,"PHASE4":3100,"NA":3102},{"trials":3093,"activeCount":74},[],{"trials":3095,"activeCount":74},[],{"trials":3097,"activeCount":74},[],{"trials":3099,"activeCount":74},[],{"trials":3101,"activeCount":74},[],{"trials":3103,"activeCount":74},[3104],{"nctId":3105,"briefTitle":3106,"status":82,"phases":3107,"primaryCompletion":84,"completion":3108,"start":882,"enrollment":19,"conditions":3109,"interventions":3110},"NCT00659165","Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes",[66],"2011-01",[33],[3090,3111],"Insulin Glargine",{"intervention":3111,"totalTrials":105,"cells":3113},{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3124},{"trials":3115,"activeCount":74},[],{"trials":3117,"activeCount":74},[],{"trials":3119,"activeCount":74},[],{"trials":3121,"activeCount":74},[],{"trials":3123,"activeCount":74},[],{"trials":3125,"activeCount":74},[3126],{"nctId":3105,"briefTitle":3106,"status":82,"phases":3127,"primaryCompletion":84,"completion":3108,"start":882,"enrollment":19,"conditions":3128,"interventions":3129},[66],[33],[3090,3111],{"intervention":3131,"totalTrials":105,"cells":3132},"Standard Oral pain medications",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3134,"activeCount":74},[],{"trials":3136,"activeCount":74},[],{"trials":3138,"activeCount":74},[],{"trials":3140,"activeCount":74},[],{"trials":3142,"activeCount":74},[],{"trials":3144,"activeCount":74},[3145],{"nctId":3146,"briefTitle":3147,"status":82,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":3151,"conditions":3152,"interventions":3154},"NCT02312739","Nitrous Oxide for Pain Management During In-office Transcervical Sterilization",[66],"2015-03","2014-02",72,[25,3153],"Inhalation of Nitrous Oxide",[3131,3155],"Intramuscular Ketorolac",{"intervention":3155,"totalTrials":105,"cells":3157},{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3159,"activeCount":74},[],{"trials":3161,"activeCount":74},[],{"trials":3163,"activeCount":74},[],{"trials":3165,"activeCount":74},[],{"trials":3167,"activeCount":74},[],{"trials":3169,"activeCount":74},[3170],{"nctId":3146,"briefTitle":3147,"status":82,"phases":3171,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":3151,"conditions":3172,"interventions":3173},[66],[25,3153],[3131,3155],{"intervention":3175,"totalTrials":105,"cells":3176},"Rnalozine",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3178,"activeCount":74},[],{"trials":3180,"activeCount":74},[],{"trials":3182,"activeCount":74},[],{"trials":3184,"activeCount":74},[],{"trials":3186,"activeCount":74},[],{"trials":3188,"activeCount":74},[3189],{"nctId":3190,"briefTitle":3191,"status":82,"phases":3192,"primaryCompletion":3193,"completion":3193,"start":3194,"enrollment":11,"conditions":3195,"interventions":3200},"NCT01815957","Impact of Ranolazine on Coronary Microcirculatory Resistance",[66],"2016-03","2012-05",[3196,3197,3198,3199],"Coronary Microcirculation","Coronary Artery Disease","Myocardial Disease","Ischemia",[3175],{"intervention":3202,"totalTrials":105,"cells":3203},"Povidone-Iodine",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3205,"activeCount":74},[],{"trials":3207,"activeCount":74},[],{"trials":3209,"activeCount":74},[],{"trials":3211,"activeCount":74},[],{"trials":3213,"activeCount":74},[],{"trials":3215,"activeCount":74},[3216],{"nctId":3217,"briefTitle":3218,"status":82,"phases":3219,"primaryCompletion":3220,"completion":3220,"start":3221,"enrollment":3222,"conditions":3223,"interventions":3224},"NCT02391714","Nitrous Oxide for Pain Management of Intrauterine Device (IUD) Insertion",[66],"2014-08","2013-10",80,[25],[3202,3225],"Chlorhexidine",{"intervention":3225,"totalTrials":105,"cells":3227},{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3229,"activeCount":74},[],{"trials":3231,"activeCount":74},[],{"trials":3233,"activeCount":74},[],{"trials":3235,"activeCount":74},[],{"trials":3237,"activeCount":74},[],{"trials":3239,"activeCount":74},[3240],{"nctId":3217,"briefTitle":3218,"status":82,"phases":3241,"primaryCompletion":3220,"completion":3220,"start":3221,"enrollment":3222,"conditions":3242,"interventions":3243},[66],[25],[3202,3225],{"intervention":3245,"totalTrials":105,"cells":3246},"Misoprostol",{"EARLY_PHASE1":3247,"PHASE1":3249,"PHASE2":3251,"PHASE3":3253,"PHASE4":3255,"NA":3257},{"trials":3248,"activeCount":74},[],{"trials":3250,"activeCount":74},[],{"trials":3252,"activeCount":74},[],{"trials":3254,"activeCount":74},[],{"trials":3256,"activeCount":74},[],{"trials":3258,"activeCount":74},[3259],{"nctId":3260,"briefTitle":3261,"status":82,"phases":3262,"primaryCompletion":3263,"completion":1886,"start":315,"enrollment":3264,"conditions":3265,"interventions":3266},"NCT01307111","Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women",[66],"2013-02",85,[128],[3245],{"intervention":3268,"totalTrials":105,"cells":3269},"Combined estrogen-progestin pill",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3271,"activeCount":74},[],{"trials":3273,"activeCount":74},[],{"trials":3275,"activeCount":74},[],{"trials":3277,"activeCount":74},[],{"trials":3279,"activeCount":74},[],{"trials":3281,"activeCount":74},[3282],{"nctId":3283,"briefTitle":3284,"status":82,"phases":3285,"primaryCompletion":489,"completion":489,"start":3286,"enrollment":3287,"conditions":3288,"interventions":3290},"NCT01465022","Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial",[66],"2005-01",197,[3289,25],"Breast Feeding",[3268,3291],"Progestin-only pill",{"intervention":3291,"totalTrials":105,"cells":3293},{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3300,"PHASE4":3302,"NA":3304},{"trials":3295,"activeCount":74},[],{"trials":3297,"activeCount":74},[],{"trials":3299,"activeCount":74},[],{"trials":3301,"activeCount":74},[],{"trials":3303,"activeCount":74},[],{"trials":3305,"activeCount":74},[3306],{"nctId":3283,"briefTitle":3284,"status":82,"phases":3307,"primaryCompletion":489,"completion":489,"start":3286,"enrollment":3287,"conditions":3308,"interventions":3309},[66],[3289,25],[3268,3291],{"intervention":3311,"totalTrials":105,"cells":3312},"nedocromil budesonide",{"EARLY_PHASE1":3313,"PHASE1":3315,"PHASE2":3317,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3314,"activeCount":74},[],{"trials":3316,"activeCount":74},[],{"trials":3318,"activeCount":74},[],{"trials":3320,"activeCount":74},[],{"trials":3322,"activeCount":74},[],{"trials":3324,"activeCount":74},[3325],{"nctId":3326,"briefTitle":3327,"status":82,"phases":3328,"completion":3329,"start":3330,"conditions":3331,"interventions":3333},"NCT00135681","Immune Dysregulation in Children and Adults With Asthma",[66],"2001-11","1996-12",[3332,21],"Asthma",[3311],{"intervention":3335,"totalTrials":105,"cells":3336},"Xolair",{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3338,"activeCount":74},[],{"trials":3340,"activeCount":74},[],{"trials":3342,"activeCount":74},[],{"trials":3344,"activeCount":74},[],{"trials":3346,"activeCount":74},[],{"trials":3348,"activeCount":74},[3349],{"nctId":3350,"briefTitle":3351,"status":82,"phases":3352,"primaryCompletion":489,"completion":489,"start":3353,"enrollment":988,"conditions":3354,"interventions":3355},"NCT00189228","Immune Dysfunction in Allergic Asthma",[66],"2005-09",[3332],[3335],{"intervention":3357,"totalTrials":105,"cells":3358},"Prazosin",{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3363,"PHASE3":3365,"PHASE4":3367,"NA":3369},{"trials":3360,"activeCount":74},[],{"trials":3362,"activeCount":74},[],{"trials":3364,"activeCount":74},[],{"trials":3366,"activeCount":74},[],{"trials":3368,"activeCount":74},[],{"trials":3370,"activeCount":74},[3371],{"nctId":3372,"briefTitle":3373,"status":82,"phases":3374,"primaryCompletion":3375,"completion":3376,"start":198,"enrollment":8,"conditions":3377,"interventions":3379},"NCT01916941","Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin",[66],"2016-08","2017-09",[3378],"Alcohol Use Disorder",[3357],{"intervention":3381,"totalTrials":105,"cells":3382},"Bumetanide",{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3387,"PHASE3":3389,"PHASE4":3391,"NA":3393},{"trials":3384,"activeCount":74},[],{"trials":3386,"activeCount":74},[],{"trials":3388,"activeCount":74},[],{"trials":3390,"activeCount":74},[],{"trials":3392,"activeCount":74},[],{"trials":3394,"activeCount":74},[3395],{"nctId":3396,"briefTitle":3397,"status":1025,"phases":3398,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":1664,"conditions":3401,"interventions":3403},"NCT02593526","Diuretic\u002FCool Dialysate Trial",[66],"2022-05-27","2017-01",[3402],"Chronic Kidney Insufficiency",[3381]]